NCT02158988View on ClinicalTrials.gov

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis

PHASE3CompletedINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

March 1, 2014

Primary Completion Date

October 1, 2020

Study Completion Date

June 9, 2021

Conditions

Malignant Neoplasm of StomachSecondary Malignant Neoplasm of PeritoneumSecondary Malignant Neoplasm of Other and Unspecified Sites

Interventions

PROCEDURE

HIPEC

"HIPEC:~Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied."

Trial Locations (1)

10117

Klinik für Allgemein-, Visceral-, Gefäß- und ThoraxchirurgieCharité Campus Mitte, Berlin

All Listed Sponsors

collaborator

German Cancer Aid

OTHER

lead

Charite University, Berlin, Germany

OTHER

NCT02158988 - Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis | Biotech Hunter | Biotech Hunter